UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000027100
Receipt number R000031059
Scientific Title Aflibercept treat and extend for macular edema secondary to branch retinal vein occlusion
Date of disclosure of the study information 2017/04/24
Last modified on 2017/04/22 13:01:26

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Aflibercept treat and extend for macular edema secondary to branch retinal vein occlusion

Acronym

Aflibercept treat and extend for branch retinal vein occlusion

Scientific Title

Aflibercept treat and extend for macular edema secondary to branch retinal vein occlusion

Scientific Title:Acronym

Aflibercept treat and extend for branch retinal vein occlusion

Region

Japan


Condition

Condition

branch retinal vein occlusion

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate best corrected visual acuity and retinal sensitivity at 12 months after intravitreal aflibercept treat and extend vs PRN for macular edema secondary to branch retinal vein occlusion

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change in best corrected visual acuity at 12 months after intravitreal aflibercept

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

aflibercept treat and extend

Interventions/Control_2

aflibercept prn

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

1.Naive BRVO
2.BCVA 0.1-1.0
3.Disease duration < 3 months
4.NPA< 5DD

Key exclusion criteria

1.Past history of vitrectomy or glaucoma surgery
2.Cataract surgery within 3 months
3.patients with diabetic retinopathy or central vein occlusion
4.IOP poor control

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tsutomu Sakai

Organization

Jikei daisan hospital

Division name

Ophthalmology

Zip code


Address

4-11-1 izsumihoncho, komae, Tokyo

TEL

0334801151

Email

tstmski@jikei.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Tsutomu Sakai

Organization

Jikei daisan hospital

Division name

Ophthalmology

Zip code


Address

4-11-1 izsumihoncho, komae, Tokyo

TEL

0334801151

Homepage URL


Email

tstmski@jikei.ac.jp


Sponsor or person

Institute

Jikei daisan hospital

Institute

Department

Personal name



Funding Source

Organization

Bayer

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 04 Month 24 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Date of protocol fixation

2016 Year 11 Month 14 Day

Date of IRB


Anticipated trial start date

2017 Year 04 Month 24 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 04 Month 22 Day

Last modified on

2017 Year 04 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031059


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name